Blonanserin

Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 and serotonin 5-HT2 receptors antagonist properties. (In Vitro) :Blonanserin exerts some blockade of α1-adrenergic receptors (Ki=26.7 nM) and also shows significant affinity for the D3 receptor (Ki=0.494 nM) . Blonanserin possesses low affinity for the sigma receptor (IC50=286 nM), but lacks significant affinity for numerous other sites including the 5-HT1A, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, and mACh receptors and the monoamine transporters. (In Vivo) :Blonanserin (oral gavage; 1 mg/kg; 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice.